About Inflammasome Therapeutics
Inflammasome Therapeutics is a private company based in Newton, Massachusetts. It has reported $19,402,417 raised in three offerings on Form D since August 2023.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | May 4, 2026 | $13,155,645fully sold | 62 | $212K | EquityRule 506(b) | Form D ↗ |
| Dec 2, 2024 | Mar 17, 2025 | $2,450,172of $10.0M target | 27 | $90,747 | EquityRule 506(b) | Form D ↗ |
| Aug 4, 2023 | Aug 14, 2023amended Jan 26, 2024 | $3,796,600fully sold | 24 | $158K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $19,402,417 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Inflammasome Therapeutics's Form D filed May 4, 2026.
Balamurali Ambati
Board Member
Jayakrishna Ambati
Co-Founder and Board Member
Chaniyilparampu Ramchand
Board Member
Napoleone Ferrara
Board Member
Earlier filings also listed Paul Ashton (chief executive officer and director, last listed Mar 2025), Mary Weber (director, last listed Mar 2025) and Joon Lee (director, last listed Mar 2025).